Publications by authors named "Stephen M Ansell"

100Publications

Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.

Cancer Treat Rev 2020 Aug 30;88:102042. Epub 2020 May 30.

Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102042DOI Listing
August 2020

Role of Microenvironment in Non-Hodgkin Lymphoma: Understanding the Composition and Biology.

Cancer J 2020 May/Jun;26(3):206-216

From the Division of Hematology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000446DOI Listing
June 2020

Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.

Authors:
Stephen M Ansell

Am J Hematol 2020 08 8;95(8):978-989. Epub 2020 Jun 8.

Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25856DOI Listing
August 2020

Immunomodulators in Lymphoma.

Curr Treat Options Oncol 2020 03 19;21(4):28. Epub 2020 Mar 19.

Division of Hematology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-020-0720-8DOI Listing
March 2020

Immunotherapy of lymphomas.

J Clin Invest 2020 Apr;130(4):1576-1585

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI129206DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108914PMC
April 2020

Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma.

Leuk Lymphoma 2020 05 8;61(5):1063-1074. Epub 2020 Jan 8.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1709832DOI Listing
May 2020

Activation-induced T-cell exhaustion: too much of a good thing?

Authors:
Stephen M Ansell

Leuk Lymphoma 2020 02 17;61(2):255-256. Epub 2019 Dec 17.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1703973DOI Listing
February 2020

The potential role of glycogen metabolism in diffuse large B-cell lymphoma.

Leuk Lymphoma 2020 05 17;61(5):1028-1036. Epub 2019 Dec 17.

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1702185DOI Listing
May 2020

The immune landscape and response to immune checkpoint blockade therapy in lymphoma.

Blood 2020 02;135(8):523-533

Division of Hematology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019000847DOI Listing
February 2020

CAR T-cells: Driving in the Fast Lane.

Hemasphere 2019 Jun 4;3(3):e209. Epub 2019 Jun 4.

Division of Hematology and Stem Cell Transplantation, University of Milano, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000209DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746027PMC
June 2019

Association between facility volume and mortality of patients with classic Hodgkin lymphoma.

Cancer 2020 02 12;126(4):757-764. Epub 2019 Nov 12.

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32584DOI Listing
February 2020

Immunotransplant: Preventing Unintended Consequences.

Authors:
Stephen M Ansell

Cancer Discov 2019 11;9(11):1487-1489

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-0977DOI Listing
November 2019

Pembrolizumab: living up to expectations.

Authors:
Stephen M Ansell

Blood 2019 10;134(14):1114-1115

Mayo Clinic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019002417DOI Listing
October 2019

Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.

Leuk Lymphoma 2020 02 13;61(2):298-308. Epub 2019 Sep 13.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1663419DOI Listing
February 2020

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

Genet Epidemiol 2019 10 13;43(7):844-863. Epub 2019 Aug 13.

Center for Neuroengineering and Therapeutics, Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gepi.22242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763347PMC
October 2019

An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.

Cancer Immunol Res 2019 09 5;7(9):1511-1522. Epub 2019 Aug 5.

Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City, Iowa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726511PMC
September 2019

The Highs and Lows of Immune-Checkpoint Blockade in Lymphoma.

Authors:
Stephen M Ansell

Cancer Immunol Res 2019 05;7(5):696-700

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-18-0890DOI Listing
May 2019

Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas.

Leuk Lymphoma 2019 11 1;60(11):2599-2601. Epub 2019 May 1.

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1608534DOI Listing
November 2019

Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis.

Leuk Res 2019 06 4;81:1-9. Epub 2019 Apr 4.

Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, United States; Department of Medical Oncology, Mayo Clinic 200 First St. SW, Rochester, MN, 55905.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.009DOI Listing
June 2019

Immunotherapy in Hodgkin Lymphoma: The Road Ahead.

Authors:
Stephen M Ansell

Trends Immunol 2019 05 2;40(5):380-386. Epub 2019 Apr 2.

Division of Hematology, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2019.03.003DOI Listing
May 2019

Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?

Authors:
Stephen M Ansell

Leuk Lymphoma 2019 05 11;60(5):1114-1115. Epub 2019 Jan 11.

a Division of Hematology , Mayo Clinic , Rochester , Minnesota 55905 , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1543887DOI Listing
May 2019

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.

Authors:
Stephen M Ansell

Lancet Haematol 2019 Jan;6(1):e2-e3

Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30210-2DOI Listing
January 2019

Tumor Microenvironment in T-Cell Lymphomas.

Cancer Treat Res 2019;176:69-82

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-99716-2_3
Publisher Site
http://dx.doi.org/10.1007/978-3-319-99716-2_3DOI Listing
July 2019

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

J Clin Oncol 2019 01 27;37(2):144-152. Epub 2018 Nov 27.

1 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; Université de Lyon, Université Claude Bernard Lyon 1, Centre de Recherche en Cancérologie de Lyon INSERM 1052, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366812PMC
January 2019

Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia.

Nat Commun 2018 10 10;9(1):4182. Epub 2018 Oct 10.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, 20892, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-06541-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180091PMC
October 2018

Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.

Authors:
Stephen M Ansell

Cancer J 2018 Sep/Oct;24(5):249-253

From the Division of Hematology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000331DOI Listing
July 2019

The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.

Hematol Oncol Clin North Am 2018 10 25;32(5):777-786. Epub 2018 Jul 25.

Division of Hematology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2018.05.005DOI Listing
October 2018

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides.

Invest New Drugs 2019 02 26;37(1):9-16. Epub 2018 Apr 26.

Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0606-9DOI Listing
February 2019

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

J Hematol Oncol 2018 04 23;11(1):57. Epub 2018 Apr 23.

Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-018-0601-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914042PMC
April 2018

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

J Clin Oncol 2018 06 19;36(16):1603-1610. Epub 2018 Apr 19.

Matthew J. Maurer, Thomas M. Habermann, Carrie A. Thompson, Cristine Allmer, Patrick B. Johnston, Ivana N. Micallef, David J. Inwards, William R. Macon, Andrew L. Feldman, Susan L. Slager, Stephen M. Ansell, James R. Cerhan, Thomas E. Witzig, and Grzegorz S. Nowakowski, Mayo Clinic, Rochester, MN; Hervé Ghesquières and Gilles A. Salles, Université Claude Bernard, Lyon; Jean-Philippe Jais, Richard Delarue, Thierry J. Molina, Hopital Necker, Paris; Corinne Haioun, Groupe Hospitalier Mondor, Créteil; Frederic Peyrade, Centre Antoine Lacassagne, Nice; Olivier Fitoussi, Polyclinique Bordeaux Nord-Aquitaine, Bordeaux; Hervé Tilly, Centre de lutte Contre le Cancer Henri Becquerel, Rouen, France; Brian K. Link, Umar Farooq, Sergei Syrbu, and George J. Weiner, University of Iowa, Iowa City, IA; and Nicolas Ketterer, Clinique Bois-Cerf, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978469PMC
June 2018

Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management.

Authors:
Stephen M Ansell

Am J Hematol 2018 05;93(5):704-715

Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25071DOI Listing
May 2018

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

J Clin Oncol 2018 05 27;36(14):1428-1439. Epub 2018 Mar 27.

Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy; John M. Timmerman, University of California Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Winship Cancer Institute, Emory University, Atlanta, GA; Jan Paul De Boer, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands, on behalf of Lunenburg Lymphoma Phase I/II Consortium; John Kuruvilla, University of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, BC Cancer Agency, Vancouver, British Columbia, Canada; Marek Trneny, Charles University, General Hospital in Prague, Prague, Czech Republic; Kazunobu Kato, Anne Sumbul, and Benedetto Farsaci, Bristol-Myers Squibb, Princeton, NJ; and Stephen M. Ansell, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075855PMC
May 2018

Primary central nervous system vasculitis associated with lymphoma.

Neurology 2018 03 2;90(10):e847-e855. Epub 2018 Feb 2.

From the Departments of Neurology (R.D.B.), Biomedical Statistics and Informatics (T.J.H.C.), Radiology (J.H.), Hematology (S.M.A.), Anatomic Pathology (C.G.), and Rheumatology (G.G.H.), Mayo Clinic, Rochester, MN; and Rheumatology Division (C.S.), Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Italy. Dr. Salvarani is currently a visiting clinician at the Department of Neurology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000005062DOI Listing
March 2018

Advances in the understanding of IgM monoclonal gammopathy of undetermined significance.

F1000Res 2017 18;6:2142. Epub 2017 Dec 18.

Department of Medicine, Division of Hematology, Mayo Clinic , Rochester, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.12880.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785715PMC
December 2017

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia-Reply.

JAMA Oncol 2018 05;4(5):745-746

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.5100DOI Listing
May 2018

Reply to Castillo et al.

Am J Hematol 2018 03 5;93(3):E71-E73. Epub 2018 Feb 5.

Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25029DOI Listing
March 2018

Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma.

Authors:
Stephen M Ansell

Hemasphere 2017 12 20;1(1):e7. Epub 2017 Dec 20.

Division of Hematology, Mayo Clinic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745978PMC
December 2017

Acalabrutinib in mantle cell lymphoma.

Lancet 2018 02 11;391(10121):633-634. Epub 2017 Dec 11.

Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(17)33256-7DOI Listing
February 2018

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

N Engl J Med 2018 01 10;378(4):331-344. Epub 2017 Dec 10.

From the University of British Columbia and the Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, Canada (J.M.C., K.J.S.); the Department of Hematology, Jagiellonian University, Krakow (W.J.), the Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw (E.L.-M.), the Department of Hematology and Transfusion Medicine, Center of Postgraduate Medical Education, Warsaw (E.L.-M.), the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.), and the Department of Lymphoid Malignancy, the Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw (J.W.) - all in Poland; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (D.J.S., A.Y.); the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the Division of Hematology and Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea (W.S.K.); Research Innovation and Statistics, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); Petrov Research Institute of Oncology, St. Petersburg, Russia (S.A.); the Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen (Á.I.), and the Department of Hematology, National Institute of Oncology, Budapest (A.R.) - both in Hungary; the Department of Advanced Biomedical Science, Federico II University Hospital, Naples (M.P.), and the Institute of Hematology Seràgnoli, University of Bologna, Bologna (P.L.Z.) - both in Italy; the Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston (Y.O.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (T.F.); the Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis (N.L.B.); the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA (R.C.); the Department of Hematology-Oncology, Barbara Ann Karmanos Cancer Center, Detroit (R.R.); Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Sutton (D.C.), and the Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester (J.R.) - both in the United Kingdom; the Department of Clinical Development, Seattle Genetics, Bothell, WA (N.C.J., E.S.); and Oncology Clinical Research (J.S., H.A.J., D.H.) and Global Biostatistics (R.L.), Millennium Pharmaceuticals, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1708984DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819601PMC
January 2018